Moderna says RSV vaccine is 84% effective at preventing disease in older adults
Publishing timestamp: 2023-01-17 18:59:59
Summary
Moderna announced that its RSV vaccine is 83.7% effective at preventing lower respiratory tract disease in people ages 60 and older. No safety concerns have been identified during the clinical trial and Moderna plans to file for FDA approval in the first half of this year. The RSV vaccine uses the same messenger RNA technology as Moderna's successful Covid-19 shots. Moderna's stock rose nearly 7% in extended trading.
Sentiment: POSITIVE
Tickers: MRNA,
Keywords: moderna inc, breaking news: business, disease outbreaks, epidemics, u.s. economy, biotech and pharmaceuticals, business, coronavirus, health care industry, business news, pandemics, politics, biotechnology,